|
|
|
201-500 employees
View all
|
|
Biotechnology
|
|
3101 Western Ave., #600, Seattle, WA 98121, US
|
|
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO^TM is a trademark of CTI BioPharma Corp.
|
CTI BioPharma Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75%
|
The widely used CTI BioPharma email format is {f}{last} (e.g. [email protected]) with 75% adoption across the company.
To contact CTI BioPharma customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.